tiprankstipranks
Amneal Pharmaceuticals price target raised to $11 from $9 at Piper Sandler
The Fly

Amneal Pharmaceuticals price target raised to $11 from $9 at Piper Sandler

Piper Sandler raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $9 and keeps an Overweight rating on the shares. The firm notes Amneal reported Q3 adjusted diluted EPS of 16c on revenue of $702M, compared to Street estimates of 13c and $694M, respectively. The company reiterated 2024 total revenue and adjusted EBITDA guidance ranges of $2.7B-$2.8B and $610M-$630M, respectively.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App